We describe durable remission in a 29-year-old woman with recurrent metastatic ERBB2-amplified mucinous ovarian adenocarcinoma following optimal secondary cytoreduction and carboplatin/paclitaxel/trastuzumab followed by one year of maintenance trastuzumab. Here, ERBB2 is linked to ovarian mucinous adenocarcinoma.